Evidence map›Paper›PMID 40287957›Full record

ReviewBlood cancer discovery2025

Overcoming B-ALL Resistance to Targeted and Immune Therapies by Rational Combination Strategies.

Miguel Quijada-Álamo, Grace Freed, Elvin Wagenblast

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Blood cancer discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Miguel Quijada-ÁlamoDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.ORCID 0000-0002-4831-4565
Grace FreedDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.ORCID 0000-0002-3360-958X
Elvin WagenblastDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.ORCID 0000-0002-0709-2759

Funding

Overcoming Therapy Resistance in Fusion Oncoprotein Driven Pediatric LeukemiaR01CA292503 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Elvin Wagenblast · 2024 to 2026
$2.4M
Intrinsic and Extrinsic Factors Contributing to Trisomy 21 PreleukemiaR01CA290681 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Elvin Wagenblast · 2024 to 2026
$1.3M
NCI NIH HHS R01 CA290681NCI NIH HHS R01 CA292503
6 · The paper itself

Abstract

Despite the remarkable efficacy of targeted therapies and immunotherapies in B-cell acute lymphoblastic leukemia (B-ALL), relapsed and refractory cases remain a major challenge. In this review, we discuss how integrating targeted agents with immunotherapy could help overcome resistance and improve long-term patient outcomes in B-ALL.

Indexed as

Drug Resistance, NeoplasmImmunotherapyMolecular Targeted TherapyPrecursor B-Cell Lymphoblastic Leukemia-LymphomaCombined Modality TherapyHumans

Identifiers

PMID40287957
PMCPMC12209775

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.